.png)
German (DE) 
English (US) 
Spanish (ES) 
French (FR) 
Hindi (IN) 
Italian (IT) 
Russian (RU) Vardah Gill
Sun, May 18, 2025, 1:16 PM 2 min read
In This Article:
Daniel Loeb’s hedge fund, Third Point, has taken a significant position in Kenvue Inc. (NYSE:KVUE), acquiring 8.9 million shares valued at over $213 million, signaling interest in potential mergers or strategic shifts aimed at boosting shareholder returns.
Meanwhile, Toms Capital Investment Management also made a notable move during the first quarter, purchasing 14.4 million shares worth $345.6 million. According to its 13F filing, Kenvue Inc. (NYSE:KVUE) is now the firm’s second-largest holding, accounting for 10.5% of its portfolio.
Sources familiar with the matter said Toms Capital is encouraging Kenvue to explore strategic options, including the potential sale of the company or parts of it.
The New Jersey-based consumer health firm became fully independent in 2023 following its spin-off from Johnson & Johnson. While the separation raised some initial uncertainty, the company shows promise of emerging as a solid standalone business, thanks in part to the rapid growth of its Skin Health and Beauty divisions. In addition, Kenvue Inc. (NYSE:KVUE) has inherited Johnson & Johnson’s track record of dividend growth after becoming independent. In 2024, the company hiked its quarterly dividend by 2.5%, which took its dividend growth streak to 63 years. It currently pays a quarterly dividend of 0.205 per share and has a dividend yield of 3.39%, as of May 18.
While we acknowledge the potential of KVUE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KVUE and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Mid-Cap Dividend Aristocrats to Invest in Now and Dividend Challengers 2025: Top 25
Disclosure. None.
Comments